A randomized, double-blinded, placebo-controlled, single ascending dose study to evaluate the pharmacokinetics, safety and tolerability, effect of food and absolute bioavailability of BMS-986238 in healthy participants
Latest Information Update: 01 Oct 2024
At a glance
- Drugs PD-L1-targeting-therapuetic-peptide-Bristol-Myers-Squibb/PeptiDream (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 01 Oct 2024 Last checked against ISRCTN: Current Controlled Trials record.
- 26 Sep 2024 Status changed from recruiting to discontinued.
- 13 Dec 2022 New trial record